Read the New York Times article about TRAILBLAZER-ALZ: Eli Lilly and GAP work together to innovate in the face of mounting enrollment challenges

The TRAILBLAZER-ALZ research study is looking at 2 investigational drugs for people having problems with memory loss or confusion.

If you are worried that your memory loss is more than just ordinary forgetfulness, or if you have been diagnosed with early stages of Alzheimer’s disease, we would like to speak with you and see if you might be interested in participating in the TRAILBLAZER-ALZ Study.

The TRAILBLAZER-ALZ Study will examine if the 2 investigational drugs, either alone or used together, may help to slow or stop memory loss.

This is a novel approach, because it will be the first time researchers have looked at these 2 investigational drugs together. Researchers want to investigate if using both drugs together might work better than using just one. 

The TRAILBLAZER-ALZ Study will include about 375 participants in the United States and Canada.

There is no cost to participate. Participants will receive all study-related care from a research doctor at no cost, and may be compensated per study site visit for time and travel expenses.
 

Who can join the TRAILBLAZER-ALZ Study?

You may be able to take part if you:

  • are 60–85 years of age
  • have had memory loss for 6 months or more that has become gradually worse over time
  • have a family member or close friend who is with you at least 10 hours per week and can attend study appointments with you.